Pharmaceutical rivals don’t often come to each other’s defense. But after the US Department of Health and Human Services ...

Kindler and his wife, Sharon Sullivan, who works in the performing arts, have listed a four-bedroom, four-bath condo on West ...

Pfizer CEO Dr. Albert Bourla speaks to CNN’s Meg Tirrell about pushing past vaccine skepticism to work with the Trump ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Albert Bourla said Pfizer is being "frugal" with investments because of the uncertainty surrounding tariffs.

Results from the Phase III VERITAC-2 trial demonstrated that vepdegestrant reduced the risk of disease progression or death ...

A colon cancer study highlighted the importance of the National Cancer Institute, while cancer doctors got a look at a ...

Vepdegestrant showed a benefit for patients with ER-positive, HER2-negative, ESR1-mutated breast cancer who had previously received endocrine-based therapy.

While vepdegestrant outperformed a standard treatment option in a subtype of patients, the benefit on progression-free ...

Pfizer (PFE) and Arvinas (ARVN) aim to seek FDA approval for thier breast cancer therapy vepdegestrant in H2 2025. Read more ...

China continues to be a source of innovation as Pfizer strikes biggest pact yet; HHS provides more info on Trump’s Most Favored Nation executive order; FDA Commissioner Marty Makary and CBER director ...

In today’s CEO Daily: Diane Brady talks to Pfizer CEO Albert Bourla about defending science amid a backdrop of political threats. The big story: Trump’s tariff regime is open to compromises.